Interferon Therapy in Herpes Virus Infections

  • Milan Fiala
  • Satya N. Chatterjee


Interferon (IFN’s) are a family of proteins secreted by vertebrate cells antigenic or mitogenic stimulation, or stimulation by synthetic compounds, intracellular infection, microbial polysaccharides, or endotoxins. They show broad, partially species-specific antiviral activity by inducing certain cellular enzymes. Additionally, IFN exerts many regulatory functions (1).


Herpes Zoster Renal Transplant Recipient Herpes Genitalis Interferon Therapy Herpes Virus Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Vilcek, J., Gresser, I., and Merigan, T.C. Regulatory functions of interferons. Annals NY Acad. Sci., 350:, 1980.Google Scholar
  2. 2.
    Lawn, R.M., Gross, M., Houck, C.M., Franke, A.E. et al. DNA sequence of a major human leukocyte interferon gene. Proc. Natl. Acad. Sci., 78:5435, 1981.PubMedCrossRefGoogle Scholar
  3. 3.
    Ohno, S. and Taniguchi, T. Structure of a chromosomal gene for human interferon beta. Proc. Natl. Acad. Sci. USA, 78:5305, 1981.PubMedCrossRefGoogle Scholar
  4. 4.
    Yip, Y.K., Barroclough, B.S., Urban, C., and Vilcek, J. Molecular weight of human gamma interferon is similar to that of other human interferons. Science, 215:411, 1982.PubMedCrossRefGoogle Scholar
  5. 5.
    Gray, P.W., Leung, D.N., Yelverton, E. et al. Expression of human immune interferon cDNA in E. coli and monkey cells. Nature, 295:503, 1982.PubMedCrossRefGoogle Scholar
  6. 6.
    Gresser, I. On the varied biological effects of interferon. Cell. Immunol., 40:406, 1977.CrossRefGoogle Scholar
  7. 7.
    Harfast, B., Muddlestone, J.R., Casali, P., Merigan, T.C., and Oldstone, M.B.A. Interferon acts directly on human B lymphocytes to modulate immunoglobulin synthesis. J. Immunol., 127:2146, 1981.PubMedGoogle Scholar
  8. 8.
    Herberman, R.B., Ortaldo, J.R., Mantovani, A. et al. Effect of human recombinant interferon on cytoxic activity of natural killer (NK) cells and monocytes. Cell. Immunol., 67:160, 1982.PubMedCrossRefGoogle Scholar
  9. 9.
    Maluish, A.E., Ortaldo, J.R., Sherwin, S. et al. Immunological monitoring of patients receiving recombinant leukocyte A interferon. Abstracts of the 1982 ASCO meeting, St. Louis, 1982.Google Scholar
  10. 10.
    Troyl, M. Enhanced human NK cell activity following treatment with interferon in vitro and in vivo. In: Mediation of Cellular Immunity in Cancer by Immune Modifiers.Google Scholar
  11. 11.
    Sonnenbeld, G. and Merigan, T.C. A regulatory role for interferon in immunity. Annals NY Acad. Sci., 332:345, 1979.CrossRefGoogle Scholar
  12. 12.
    Overall, J.C., Yeh, T.J., and Kern, E.R. Sensitivity of Herpes simplex virus types I and II to three preparations of human interferon. J. Infect. Dis., 142:943, 1980.PubMedCrossRefGoogle Scholar
  13. 13.
    Weck, P.K., Rinderknecht, E., Estell, D.A., and Stebbing, N. Antiviral activity of bacteria-derived human alpha interferons against encephalorayocarditis virus infection of mice. Infect. Immunol., 35:660, 1982.Google Scholar
  14. 14.
    Sullivan, J.L., Byron, K.S., Brewster, F.E., Sakamoto, K., Shaw, J.E., and Pagano, J.S. Treatment of life-threatening Epstein-Barr virus infections with Acyclovir®. Am. J. Med., 73:262, 1982.PubMedCrossRefGoogle Scholar
  15. 15.
    Hammer, S.M., Kaplan, J.C., Lowe, B.R., and Hirsch, M.S. Alpha interferon and Acyclovir treatment of Herpes simplex virus in lymphoid cell cultures. Antimicrob. Ag. Chemother., 21:634, 1982.Google Scholar
  16. 16.
    Spector, S.A., Tyndall, M., and Kelley, E. Effect of Acyclovir-combined with other antiviral agents on human cytomegalovirus. Am. J. Med., 73:36, 1982.PubMedCrossRefGoogle Scholar
  17. 17.
    Smith, C.I., Kitchen, L.W., Scullard, G.H., Robinson, W.S., Gregory, P.B., and Merigan, T.C. Vidarabine monophosphate and human leukocyte interferon in chronic hepatitis B infection. J. Am. Med. Assoc., 247:2261, 1982.CrossRefGoogle Scholar
  18. 18.
    Smolin, G., Stebbing, N., Friedlaender, M., Friedlaender, R., and Okumoto, M. Natural and cloned human leukocyte interferon in herpes virus infections of rabbit eyes. Arch. Ophtalmol, 100:481, 1982.CrossRefGoogle Scholar
  19. 19.
    Nesburn, A.B. and Ziniti, P.J. Long-term topical poly 1:C in experimental chronic ocular herpes simplex infection. Am. J. Ophthalmol., 72:821, 1971.PubMedGoogle Scholar
  20. 20.
    Trousdale, M.D., Dunkel, E.C., and Nesburn, A.B. Effect of Acyclovir on acute and latent herpes simplex virus infections in the rabbit. Invest. Ophthalmol. Vis. Sci. 19:1336, 1980.PubMedGoogle Scholar
  21. 21.
    Wohlenberg, C., Openshaw, H., and Notkins, A.L. In vitro system for studying the efficacy of antiviral agents in preventing the reactivation of latent herpes simplex virus. Antimicrob. Ag. Chemother., 15:625, 1979.Google Scholar
  22. 22.
    Merigan, T.C. and Cunningham, A.L. Interferons as markers for immune response in man to viral antigens. Presented at the WHO Scientific Group on the Relevance of Recent Progress in Vaccines and Antiviral Drugs to the Prevention and Control of Viral Disease, London 5–9, July 1982.Google Scholar
  23. 23.
    Merigan, T.C. Present appraisal and future hopes for the clinical utilization of interferons. In: I. Gresser (ed.), Interferon III. New York: Academic Press, 1981.Google Scholar
  24. 24.
    Pazin, G.J., Armstrong, J.A., Lam, M.T., Tarr, G.C., Janetta, P.J., and Ho, M. Prevention of reactivated herpes simplex infection by human leukocyte interferon after operation on the trigeminal root. N. Engl. J. Med., 301:225, 1979.PubMedCrossRefGoogle Scholar
  25. 25.
    Sundmacher, R., Cantell, K., and Neumann-Haefflin, D. Combination therapy of dendritic keratitis in trifluorothymidine and interferon. Lancet, ii:687, 1978.CrossRefGoogle Scholar
  26. 26.
    Sundmacher, R., Cantell, K., Skoda, R., Hallermann, C., and Neumann-Haefelin, D. Human leukocyte and fibroblast interferon in a combination therapy of dendritic keratitis. Albrecht von Graefes Arch. Klin. Ophthalmol. 208:229, 1978.Google Scholar
  27. 27.
    Arvin, A.M., Kushner, J.H., Feldman, S., Baehner, R.L., Hammond, D., and Merigan, T.C. Human leukocyte interferon for the treatment of varicella in children with cancer. N. Engl. J. Med. 306:761, 1982.PubMedCrossRefGoogle Scholar
  28. 28.
    Arvin, A.M., Martin, D.P., and Merigan, T.C. Interferon prophyulaxis for varicella infection in Erythrocebus patas monkeys. J. Infect. Dis., in press, 1982.Google Scholar
  29. 29.
    Merigan, T.C., Rand, K.H., Pollard, R.B., Abdallah, P.S., Jordan, G.W., and Fried, R.P. Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. N. Engl. J. Med., 298:981, 1978.PubMedCrossRefGoogle Scholar
  30. 30.
    Merigan, T.C., Gallagher, J.G., Pollard, R.B., and Arvin, M. Short-course human leukocyte interferon in treatment of herpes zoster in patients with cancer. Antimicrob. Ag. Chemother., 19:193, 1981.Google Scholar
  31. 31.
    Stevens, D.A. and Merigan, T.C Interferon, antibody and other host factors in herpes zoster. J. Clin. Invest. 51:1170, 1972.PubMedCrossRefGoogle Scholar
  32. 32.
    Balfour, H.H., Bean, B., Mitchell, C.D., Sachs, G.W., Boen, J.R., and Edelman, C.K. Acyclovir in immunocompromised patients with cytomegalovirus disease. A controlled trial at one institution. Am. J. Med., 73:241, 1982.Google Scholar
  33. 33.
    Cheeseman, S.H., Rubin, R.H., Stewart, J.A., Tolkoff-Rubin, N.E., Cosimi, A.B., Cantell, K., Gilbert, J., Winkle, S., Herrin, J.T., Black, P.H., Russell, P.S., and Hirsch, M.S. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. N. Engl. J. Med., 300:1345, 1979.PubMedCrossRefGoogle Scholar
  34. 34.
    Hirsch, M.S., Schooley, R.T., Rubin, R.H., Tolkoff-Rubin, N., and Cantell, K. Interferon in renal transplant recipients. Presented at the Interferon meeting, Squaw Valley, March 1982.Google Scholar
  35. 35.
    Meyers, J.D., McGuffin, R.W., Neumann, P.E., Singer, J.W., and Thomas, E.D. Toxicity and efficacy of human leukocyte interferon for treatment of cytomegalovirus pneumonia after marrow transplantation. J. Infect. Dis., 141:555, 1980.PubMedCrossRefGoogle Scholar
  36. 36.
    Chou, S. and Merigan, T.C. Preliminary observations on the effect of human leukocyte interferon on viral excretion in CMV retinitis. Abstracts of the 6th Cold Spring Harbor meeting on herpes viruses, 1982.Google Scholar
  37. 37.
    Lopez, C., Fitzgerald, P.A., and Siegal, F.P. Severe acquired immunodeficiency syndrome in male homosexuals: diminished capacity to make interferon-alpha in vitro is associated with susceptibility to opportunistic infections. Submitted for publication 1982.Google Scholar
  38. 38.
    Thorley-Lawson, D. The transformation of adult but not newborn human lymphocytes by Epstein-Barr virus and phytohemagglutinin is inhibited by interferon: the early suppression by T cells of Epstein-Barr infection is mediated by interferon. J. Immunol., 126:829, 1981.PubMedGoogle Scholar
  39. 39.
    Hanto, D.W., Frizzera, G., Gajl-Peczalska, K.J., Sakamoto, K., Purtilo, D.T., Balfour, H.H., Simmons, R.L., and Najarian, J.S. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: Acyclovir therapy and transition from polyclonal to monoclonal B cell proliferation. N. Engl. J. Med., 306:913, 1982.PubMedCrossRefGoogle Scholar
  40. 40.
    Thestrup-Pederson, K., Esmann, V., Bisballe, S., Jensen, J.R., Pallesen, G., Hastrup, J., Madsen, M., Thorling, K., Grazia-Masucci, M., Saemundsen, A.K., and Ernberg, I. Epstein-Barr virus-induced lymphoproliferative disorder converting to fatal Burkitt-like lymphoma in a boy with interferon-inducible chromosomal defect. Lancet, ii:997, 1980.CrossRefGoogle Scholar
  41. 41.
    Cheeseman, S.H., Henle, W., Rubin, R., Tolkoff-Rubin, N.E., Cosimi, B., Cantell, K., Winkle, S., Herrin, J.T., Black, P.H., Russell, P.S., and Hirsch, M.S. Epstein-Barr virus infection in renal transplant patients: effect of antithymocyte globulin and interferon. Ann. Intern. Med., 93:39, 1980.PubMedGoogle Scholar
  42. 42.
    Rhodes-Feuillette, A., Canivet, M., Devergie, A., Gluckman, E., Mazeron, M.-C., Perol, Y., and Peries, J. Circulating interferon after marrow transplant in cytomegalovirus infection. Lancet, i:1217, 1981.CrossRefGoogle Scholar
  43. 43.
    Chatterjee, S.N. and Jordan, G.W. Interferon in the circulation of renal transplant recipients. J. Inf. Dis., in press, 1982.Google Scholar
  44. 44.
    Cantell, K. and Hirvonen, S. Large-scale production of human leukocyte interferon containing 10» units per ml. J. Gen. Virol., 39:54l, 1978.CrossRefGoogle Scholar
  45. 45.
    Gutterman, J.U., Fine, S., Quesada, J., Horning, S.J., Levine, J.F., Alexonian, R., Bernhardt, L., Kramer, M., Spiegel, H., Colburn, W., Trown, P., Merigan, T.C., and Dziewanowski, Z. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance and biological effects in cancer patients. Ann. Intern. Med., 96:549, 1982.PubMedGoogle Scholar
  46. 46.
    Scott, G.M., Secher, D.S., Flowers, D., Bate, J., Cantell, K. and Tyrrell, D.A.J. Toxicity of interferon. Br. Med. J., 282:1345, 1981.CrossRefGoogle Scholar
  47. 47.
    Gutterman, J.U., Blumenschein, G.R., Alexanian, R., Yap, H-Y., Buzdar, A.U., Cabanellas, F., Hortobagyi, G.N., Hersh, E.M., Rasmussen, S.L., Harmon, M., Kramer, M., and Pestka, S. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann. Int. Med., 93:399, 1980.PubMedGoogle Scholar
  48. 48.
    Bartram, C.R., Morier, W., and Schmidt, A. Human fibroblast interferon does not induce chromosomal abnormalities. Lancet, i:1372, 1981.CrossRefGoogle Scholar
  49. 49.
    Valibracht, A., Treuner, J., Flehmig, B., Joesters, K.E., and Niethammer, D. Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. Nature, 289:496, 1981.CrossRefGoogle Scholar
  50. 50.
    Panem, S., Check, I.J., Henriksen, D., and Vilcek, J. Antibodies to alpha-interferon in a patient with systemic lupus erythematosus. Submitted, 1982.Google Scholar
  51. 51.
    Bino, T., Edery, H., Gertler, A., and Rosenberg, H. Involvement of the kidney in catabolism of human leukocytes interferon. J. Gen. Virol., 59:39, 1982.PubMedCrossRefGoogle Scholar
  52. 52.
    Spruance, S.L., Green, J.A., Chiu, G., Yeh, T.J., Wenerstrora, G., and Overall, J.C. Jr. Pathogenesis of herpes simplex labialis: correlation of vesicle fluid interferon with lesion age and virus titer. Infect. Immunol., 36:907, 1982.Google Scholar
  53. 53.
    O’Reilly, R.J., Chibbaro, A., Anser, E., and Lopez, C. Cell-mediated immune responses in patients with recurrent herpes simplex infections. II. Infection associated deficiency of lymphokine production in patients with recurrent herpes labialis or herpes progentialis. J. Immunol., 118:1095, 1977.PubMedGoogle Scholar
  54. 54.
    Kelsey, D.R., Overall, J.C. Jr., and Glasgow, L.A. Production of alpha and gamma interferons by spleen cells from cytomegalovirus-infected mice. Infect. Immunol., 36:651, 1982.Google Scholar
  55. 55.
    Fleischmann, W.R., Georgiades, J.A., Osborne, L.C., and Johnson, H.M. Potentiation of interferon activity by mixed preparations of fibroblastic and immune interferon. Infect. Immunol., 26:248, 1979.Google Scholar
  56. 56.
    Sonnenfeld, G., Salvin, S.B., and Younger, J.S. Cellular source of interferons in circulation of mice with delayed hypersensitivity. Infect. Immunol., 18:283, 1977.Google Scholar
  57. 57.
    Trown, P.W., Dennine, R.A., Kramer, M.J., Connell, E.V., Palleroni, A.V., Quesada, J., and Gutterman, J.U. Antibodies in human leucocyte interferons in cancer patients. Lancet, i:81, 1983.CrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1984

Authors and Affiliations

  • Milan Fiala
    • 1
  • Satya N. Chatterjee
    • 1
  1. 1.Department of SurgeryUniversity of CaliforniaDavisUSA

Personalised recommendations